Invasive aspergillosis in patients with underlying liver cirrhosis: a prospective cohort study. (20th April 2017)

• Record Type: Journal Article
• Authors: Prattes, Juergen; Hoenigl, Martin; Krause, Robert; Buzina, Walter; Valentin, Thomas; Reischies, Frederike; Koidl, Christoph; Zollner-Schwetz, Ines
• Is Part Of: Medical mycology. Volume 55:Number 8(2017)
• Page Start: 803
• Page End: 812
• Publication Date: 2017-04-20
• Subjects: liver cirrhosis -- aspergillosis -- galactomannan -- prevalence -- voriconazole; Medical mycology -- Periodicals; Veterinary mycology -- Periodicals; Mycology -- Periodicals; Mycoses -- Periodicals; Pathogenic fungi -- Periodicals; 616.969005
• DOI: 10.1093/mmy/myx011
• Languages: English
• ISSNs: 1369-3786

Abstract

Abstract: The aim of this study was to determine the prevalence of invasive aspergillosis (IA) in patients with liver cirrhosis and the performance of serum galactomannan (GM) screening. Patients with decompensated liver cirrhosis and patients with compensated liver cirrhosis presenting with fever and/or respiratory symptoms were prospectively enrolled. All patients were screened by serum GM twice weekly irrespective of clinical signs and symptoms. Positive serum GM triggered work-up consisting of chest computed tomography and in case of pathological findings bronchoscopy. 150 patients were included in the study. Two (1.3%) had probable, one (0.7%) had possible, and 147 (98%) had no evidence of IA. Both patients with probable IA had compensated liver cirrhosis. Sensitivity for serum GM screening for probable versus no IA was 0.5 (95% CI, 0.09–0.91), specificity 0.97 (95% CI: 0.92–0.99), negative predictive value 0.99 (95% CI, 0.96–0.99) and positive predictive value (PPV) 0.17 (95% CI, 0.01–0.64). PPV was 0.5 (95% CI, 0.03–0.98) in patients with clinical suspicion of IA. In conclusion, prevalence of IA in patients with liver cirrhosis seems to be low. Targeted GM testing in case of clinical suspicion of IA may be associated with markedly higher PPVs when compared to universal GM screening in patients with liver cirrhosis.